| Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR CE Wainwright, JS Elborn, BW Ramsey, G Marigowda, X Huang, M Cipolli, ... New England Journal of Medicine 373 (3), 220-231, 2015 | 1516 | 2015 |
| Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind … HGM Heijerman, EF McKone, DG Downey, E Van Braeckel, SM Rowe, ... The Lancet 394 (10212), 1940-1948, 2019 | 1007 | 2019 |
| Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health PA Flume, BP O'Sullivan, KA Robinson, CH Goss, PJ Mogayzel Jr, ... American journal of respiratory and critical care medicine 176 (10), 957-969, 2007 | 871* | 2007 |
| Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations PA Flume, PJ Mogayzel Jr, KA Robinson, CH Goss, RL Rosenblatt, ... American journal of respiratory and critical care medicine 180 (9), 802-808, 2009 | 825 | 2009 |
| European cystic fibrosis society standards of care: best practice guidelines AR Smyth, SC Bell, S Bojcin, M Bryon, A Duff, P Flume, N Kashirskaya, ... Journal of cystic fibrosis 13, S23-S42, 2014 | 755 | 2014 |
| ECFS best practice guidelines: the 2018 revision C Castellani, AJA Duff, SC Bell, HGM Heijerman, A Munck, F Ratjen, ... Journal of cystic fibrosis 17 (2), 153-178, 2018 | 731 | 2018 |
| Pulmonary complications after esophagectomy CE Avendano, PA Flume, GA Silvestri, LB King, CE Reed The Annals of thoracic surgery 73 (3), 922-926, 2002 | 436 | 2002 |
| Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial MW Konstan, PA Flume, M Kappler, R Chiron, M Higgins, F Brockhaus, ... Journal of Cystic Fibrosis 10 (1), 54-61, 2011 | 421 | 2011 |
| Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation PA Flume, TG Liou, DS Borowitz, H Li, K Yen, CL Ordoñez, DE Geller, ... Chest 142 (3), 718-724, 2012 | 408 | 2012 |
| Cystic fibrosis pulmonary guidelines: airway clearance therapies PA Flume, KA Robinson, BP O'Sullivan, JD Finder, RL Vender, ... Respiratory care 54 (4), 522-537, 2009 | 389 | 2009 |
| Treatment of lung infection in patients with cystic fibrosis: current and future strategies G Döring, P Flume, H Heijerman, JS Elborn, Consensus Study Group Journal of Cystic Fibrosis 11 (6), 461-479, 2012 | 354 | 2012 |
| Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research AT Hill, CS Haworth, S Aliberti, A Barker, F Blasi, W Boersma, ... European Respiratory Journal 49 (6), 2017 | 338 | 2017 |
| Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax PA Flume, PJ Mogayzel Jr, KA Robinson, RL Rosenblatt, L Quittell, ... American journal of respiratory and critical care medicine 182 (3), 298-306, 2010 | 323 | 2010 |
| Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial F Ratjen, C Hug, G Marigowda, S Tian, X Huang, S Stanojevic, CE Milla, ... The lancet Respiratory medicine 5 (7), 557-567, 2017 | 320 | 2017 |
| Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity PA Flume, JD Chalmers, KN Olivier The Lancet 392 (10150), 880-890, 2018 | 311 | 2018 |
| Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open … DE Griffith, G Eagle, R Thomson, TR Aksamit, N Hasegawa, K Morimoto, ... American journal of respiratory and critical care medicine 198 (12), 1559-1569, 2018 | 275 | 2018 |
| Massive hemoptysis in cystic fibrosis PA Flume, JR Yankaskas, M Ebeling, T Hulsey, LL Clark Chest 128 (2), 729-738, 2005 | 239 | 2005 |
| Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease KN Olivier, DE Griffith, G Eagle, JP McGinnis, L Micioni, K Liu, CL Daley, ... American journal of respiratory and critical care medicine 195 (6), 814-823, 2017 | 232 | 2017 |
| Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials AF Barker, AE O'Donnell, P Flume, PJ Thompson, JD Ruzi, J De Gracia, ... The lancet Respiratory medicine 2 (9), 738-749, 2014 | 225 | 2014 |
| Treatment of lung infection in patients with cystic fibrosis: current and future strategies G Doring, P Flume, H Heijerman, JS Elborn Journal of Cystic Fibrosis 11 (6), 461-479, 2012 | 223 | 2012 |
